Trials In Focus: FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials
Guidance Targets ‘Multiplicity Problem’
Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.
